Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 7/20 | 0.38 |
| ▸ | GRM5 | P41594 | 3/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | CALML3 | P27482 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3506560 | 1.00 | GRM2 (0.38) | GRM2GRM5F10MAOBCALML3 | |
| SCHEMBL3506565 | 0.83 | CLK1 (0.31) | — | |
| SCHEMBL8310113 | 0.81 | GRM2 (0.38) | GRM2GRM5F10MAOB | |
| SCHEMBL3505520 | 0.81 | GRM2 (0.39) | GRM2GRM5F10MAOB | |
| SCHEMBL8305067 | 0.80 | GRM2 (0.39) | GRM2GRM5F10MAOB | |
| SCHEMBL3505659 | 0.80 | GRM2 (0.39) | GRM2GRM5MAOB | |
| SCHEMBL3504921 | 0.80 | GRM2 (0.39) | GRM2GRM5MAOB | |
| SCHEMBL8305068 | 0.80 | GRM2 (0.38) | GRM2GRM5MAOB | |
| SCHEMBL3505099 | 0.80 | GRM2 (0.39) | GRM2GRM5MAOB | |
| SCHEMBL3503412 | 0.79 | GRM2 (0.38) | GRM2GRM5MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5475014-A | Monoamine oxidase inhibor; antidepressant | EISAI CO., LTD. (JP) | 1995-12-12 | — | — | US | claimed |
| US-20100247543-A1 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS, S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
| EP-2195029-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | Oryzon Genomics SA (ES) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009027349-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS SA (ES) | 2009-03-05 | — | — | WO | disclosed |